首頁 > 市場調查報告書 > 製藥

疼痛

鴉片類藥物使用障礙市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1913151

鴉片類藥物使用障礙市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道、最終用戶和地區分類）—2026-2033年產業預測

Opioid Use Disorder Market Size, Share, and Growth Analysis, By Treatment (Methadone, Buprenorphine), By Route of Administration (Oral, Injectable / Implant), By Distribution Channel, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月01日 | 出版商:

SkyQuest | 英文 175 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球鴉片類藥物使用障礙市場規模將達到 57 億美元，到 2025 年將成長至 63.7 億美元，到 2033 年將成長至 155.6 億美元，在預測期（2026-2033 年）內複合年成長率為 11.8%。

藥物濫用趨勢的上升，以及政府為提高公眾對鴉片類藥物使用障礙（OUD）的認知和擴大治療設施所做的努力，正在顯著推動市場需求。這一成長主要源於處方鴉片類藥物、海洛因和合成藥物濫用的增加，促使人們需要更全面的治療方案。全球對OUD的認知提升以及對治療方案的優先考慮，在公眾和相關人員的支持下，正在創造新的長期成長機會。治療中心、門診診所、遠端醫療服務和綜合護理計畫的激增也提高了治療的可近性，進一步推動了市場成長。然而，社會污名、發展中地區服務取得有限、治療費用高昂以及監管障礙等挑戰可能會阻礙市場擴張和滲透。

全球鴉片類藥物使用疾患市場促進因素

不斷增加的研發投入旨在開發新型藥物治療產品，這極大地促進了各種鴉片類藥物使用障礙的治療。緩釋Buprenornhine注射、創新植入、納曲酮等新型逆轉劑以及聯合治療等進展，為市場相關人員帶來了許多機會。此外，這些進展不僅降低了給藥頻率，還提高了患者的依從性，從而對全球市場前景產生了積極影響。這種對創新的日益重視正在重塑有效治療方案的格局。

限制全球鴉片類藥物使用疾患市場的因素

由於社會上對鴉片類藥物使用障礙的持續污名化，全球鴉片類藥物使用障礙市場面臨嚴峻挑戰。許多鴉片類藥物使用障礙患者因擔心受到批評、歧視和法律制裁而猶豫不決，不敢尋求治療。這種恐懼往往導致現有治療項目和服務的使用率不足。此外，文化障礙和羞恥感也會阻礙患者獲得所需的醫療服務，最終抑制市場成長和發展。消除這些社會認知對於提高治療接受度、為鴉片類藥物使用障礙患者提供更有效的醫療保健至關重要。

全球鴉片類藥物使用疾患市場趨勢

全球鴉片類藥物使用障礙市場正經歷著長效和緩釋藥物的重大轉變，這反映了臨床醫生和患者日益成長的偏好。Buprenornhine注射劑和納曲酮植入劑等創新治療方法因其高效性和安全性而備受關注。這些製劑不僅透過減少給藥頻率來提高患者的用藥依從性，還能更穩定地控制症狀，進而提高患者的接受度。隨著醫療機構擴大採用這些先進的治療方案，對長效療法的需求有望重塑市場格局，成為有效克服鴉片類藥物使用障礙的一個充滿希望的趨勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Indivior PLC
Alkermes plc
Orexo AB
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Camurus AB
Hikma Pharmaceuticals PLC
Titan Pharmaceuticals Inc.
Omeros Corporation
Mylan NV
Johnson & Johnson Services, Inc.
Boehringer Ingelheim GmbH
Purdue Pharma LP
ZLB Behring
Novartis AG
Mallinckrodt Pharmaceuticals
Sandoz
Gilead Sciences Inc.
ViiV Healthcare
Camurus AB

結論與建議

簡介目錄

Product Code: SQMIG35D2365

Global Opioid Use Disorder Market size was valued at USD 5.7 Billion in 2024 and is poised to grow from USD 6.37 Billion in 2025 to USD 15.56 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).

The increasing incidence of drug abuse, coupled with heightened government initiatives to enhance awareness and expand treatment facilities for opioid use disorder (OUD), is driving significant market demand. This surge is largely fueled by the rising misuse of prescription opioids, heroin, and synthetic drugs, necessitating more comprehensive treatment solutions. Global prioritization of OUD awareness and therapeutic options presents new long-term opportunities, supported by growing public and stakeholder advocacy. The proliferation of treatment centers, outpatient clinics, telehealth services, and integrated care programs has also enhanced access to care, further contributing to market growth. However, challenges such as social stigma, limited access in developing regions, high treatment costs, and regulatory barriers may hinder market expansion and penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Opioid Use Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Opioid Use Disorder Market Segments Analysis

Global Opioid Use Disorder Market is segmented by Treatment, Route of Administration, Distribution Channel, End-User and region. Based on Treatment, the market is segmented into Methadone, Buprenorphine, Naltrexone and Other Therapies. Based on Route of Administration, the market is segmented into Oral, Injectable / Implant and Transdermal / Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online / E-commerce. Based on End-User, the market is segmented into Outpatient Clinics, Inpatient / Residential Treatment Centres and Remote Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Opioid Use Disorder Market

The expansion of investments in research and development aimed at creating new pharmacotherapy products is significantly contributing to the treatment of various opioid use disorders. Advances such as extended-release buprenorphine injections, innovative implants, and novel antagonists like naltrexone, along with combination therapies, are opening up a multitude of opportunities for stakeholders within the market. Furthermore, these advancements not only lead to a reduction in dosing frequency but also enhance patient adherence, thus positively influencing the overall perspective of the global opioid use disorder market. This growing emphasis on innovation is shaping the landscape for effective treatment solutions.

Restraints in the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market faces significant challenges due to the persistent social stigma surrounding this condition. Many individuals grappling with opioid use disorder hesitate to seek treatment due to fears of judgment, discrimination, or potential legal repercussions. This apprehension often leads to underutilization of available treatment programs and services. Furthermore, cultural barriers and feelings of shame can further inhibit individuals from accessing necessary care, ultimately stalling the growth and development of the market. Addressing these societal attitudes is crucial for improving treatment uptake and moving towards a more effective healthcare response for those affected by opioid use disorder.

Market Trends of the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market is experiencing a significant shift toward long-acting and extended-release pharmacotherapies, reflecting a growing preference among clinicians and patients alike. Innovations such as buprenorphine injections and naltrexone implants are gaining traction due to their enhanced efficacy and safety profiles. These formulations not only improve adherence by reducing the frequency of dosing but also provide a more stable management of symptoms, leading to higher patient acceptance. As healthcare providers increasingly adopt these advanced treatment options, the demand for long-acting therapies is poised to reshape the market landscape, highlighting a promising trend in combating opioid use disorders effectively.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Opioid Use Disorder Market Size by Treatment & CAGR (2026-2033)

Market Overview
Methadone
Buprenorphine
Naltrexone
Other Therapies

Global Opioid Use Disorder Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable / Implant
Transdermal / Other

Global Opioid Use Disorder Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online / E-commerce

Global Opioid Use Disorder Market Size by End-User & CAGR (2026-2033)

Market Overview
Outpatient Clinics
Inpatient / Residential Treatment Centres
Remote Care

Global Opioid Use Disorder Market Size & CAGR (2026-2033)

North America (Treatment, Route of Administration, Distribution Channel, End-User)
- US
- Canada
Europe (Treatment, Route of Administration, Distribution Channel, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Route of Administration, Distribution Channel, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Route of Administration, Distribution Channel, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Indivior PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkermes plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orexo AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Camurus AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Titan Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Omeros Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Purdue Pharma L.P.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ZLB Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViiV Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Camurus AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments